<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00223054</url>
  </required_header>
  <id_info>
    <org_study_id>004</org_study_id>
    <nct_id>NCT00223054</nct_id>
  </id_info>
  <brief_title>Polymorphism of the Cytochrome P450-system in Renal Transplants</brief_title>
  <official_title>Polymorphism of the Cytochrome P450-system and the MDR-system in Renal Transplants Receiving the Immunosuppressive Drugs Tacrolimus, Sirolimus, Everolimus or Cyclosporine A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the researchers want to investigate genetic polymorphisms of cytochrome 450
      enzymes and the multiple drug resistance (MDR) gene in renal transplant patients to look for
      differences in dosing of immunosuppressive drugs (tacrolimus, sirolimus, everolimus,
      cyclosporine A).

      All patients who receive one of these drugs can be included and drug blood trough levels,
      dosing and genetics are compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint is the

        1. serum creatinine in patients with and without polymorphysms

        2. rate of rejections in patients with and without polymorphysms
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">200</enrollment>
  <condition>Function of Renal Transplant</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>retrospective analyze of drug levels in comparison to polymorphism</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporin A</intervention_name>
    <description>retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA samples to analyze polymorphisms
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patinets after kidney transplantation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal transplant patients receiving one or more of the following drugs:

               -  tacrolimus

               -  sirolimus

               -  everolimus

               -  cyclosporin A

               -  fluvastatin

          -  Informed consent given by the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lutz Renders, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Schleswig-Holstein, Campus Kiel, Department of Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Schleswig-Holstein, Campus Kiel, Department of Nephrology</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther. 2007 Feb;81(2):228-34. Epub 2006 Dec 27.</citation>
    <PMID>17192769</PMID>
  </results_reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>August 3, 2011</last_update_submitted>
  <last_update_submitted_qc>August 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lutz Renders</name_title>
    <organization>University of Kiel</organization>
  </responsible_party>
  <keyword>cyclosporin A</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Fluvastatin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

